Switch theme
Sign up to access all valuation multiples
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.
2016
10
LTM Revenue n/a
LTM EBITDA n/a
-$60.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Ikena Oncology has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Ikena Oncology achieved revenue of n/a and an EBITDA of -$54.1M.
Ikena Oncology expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Ikena Oncology valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $9.2M | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$74.4M | -$54.1M | XXX | XXX | XXX |
| EBITDA Margin | -812% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$68.8M | -$68.2M | XXX | XXX | XXX |
| Net Margin | -751% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Ikena Oncology's stock price is $1.
Ikena Oncology has current market cap of $56.5M, and EV of -$60.4M.
See Ikena Oncology trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$60.4M | $56.5M | XXX | XXX | XXX | XXX | $-0.95 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Ikena Oncology has market cap of $56.5M and EV of -$60.4M.
Ikena Oncology's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Ikena Oncology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Ikena Oncology and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$60.4M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | 1.1x | XXX | XXX | XXX |
| P/E | -1.1x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 1.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpIkena Oncology's NTM/LTM revenue growth is n/a
Ikena Oncology's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $5.5M for the same period.
Over next 12 months, Ikena Oncology's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Ikena Oncology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Ikena Oncology and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -100% | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | -27% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $5.5M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ikena Oncology acquired XXX companies to date.
Last acquisition by Ikena Oncology was XXXXXXXX, XXXXX XXXXX XXXXXX . Ikena Oncology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Ikena Oncology founded? | Ikena Oncology was founded in 2016. |
| Where is Ikena Oncology headquartered? | Ikena Oncology is headquartered in United States of America. |
| How many employees does Ikena Oncology have? | As of today, Ikena Oncology has 10 employees. |
| Who is the CEO of Ikena Oncology? | Ikena Oncology's CEO is Dr. Mark Manfredi, PhD. |
| Is Ikena Oncology publicy listed? | Yes, Ikena Oncology is a public company listed on NAS. |
| What is the stock symbol of Ikena Oncology? | Ikena Oncology trades under IKNA ticker. |
| When did Ikena Oncology go public? | Ikena Oncology went public in 2021. |
| Who are competitors of Ikena Oncology? | Similar companies to Ikena Oncology include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Ikena Oncology? | Ikena Oncology's current market cap is $56.5M |
| Is Ikena Oncology profitable? | Yes, Ikena Oncology is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
